CTKB (Cytek Biosciences) Forward Dividend Yield % : 0.00% (As of Dec. 15, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences Forward Dividend Yield %?

As of today (2024-12-15), the Forward Annual Dividend Yield of Cytek Biosciences is 0.00%.

As of today (2024-12-15), the Trailing Annual Dividend Yield of Cytek Biosciences is 0.00%.

CTKB's Forward Dividend Yield % is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.835
* Ranked among companies with meaningful Forward Dividend Yield % only.

Cytek Biosciences's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Cytek Biosciences's Forward Dividend Yield %

For the Medical Devices subindustry, Cytek Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytek Biosciences's Forward Dividend Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Forward Dividend Yield % falls into.

Cytek Biosciences Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Cytek Biosciences (NAS:CTKB) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Cytek Biosciences Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Cytek Biosciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytek Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

47215 Lakeview Boulevard, Fremont, CA, USA, 94538

Website

https://www.cytekbio.com

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Executives

Ming Yan	director, officer: Chief Technology Officer	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Patrick Jeanmonod	officer: Chief Financial Officer	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang	director, officer: President and CEO	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque	officer: SVP, Global Sales and Services	47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams	officer: Chief Operating Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison	director
Deborah J Neff	director	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland	officer: Chief Commercial Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper	director	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron	director	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng	director	SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116